S100A8 and familial pancreatic carcinoma: According to patient tissue microarrays and immunohistochemical detection, both S100A8 mRNA and protein levels are highly elevated in many cancers, including anaplastic thyroid carcinoma (Reeb et al., 2015), breast cancer (Wang D. et al., 2018), lung cancer (Sumardika et al., 2019), acute myeloid leukemia (Mondet et al., 2021), and pancreatic cancer (Basso et al., 2014), and associated with less survival, poor outcome, and high probability of relapse; thus, S100A8 could act as a potential biomarker for different cancers.